New KRAS Inhibitor Achieves 63% Response Rate in Deadly Pancreatic Cancer
A liposomal KRAS-G12D inhibitor combined with chemotherapy met its primary endpoint in a phase 1b/2 trial for advanced pancreatic cancer.
Summary
Pancreatic cancer is notoriously hard to treat, partly because most cases are driven by a mutated protein called KRAS-G12D. Previous drugs targeting this mutation struggled with side effects and poor tumor penetration. HRS-4642 is a new intravenous drug packaged in nanoparticles designed to accumulate more effectively in tumors. In a phase 1b/2 trial of 31 patients with advanced KRAS-G12D-mutant pancreatic cancer, combining HRS-4642 with standard chemotherapy produced a confirmed tumor response rate of 63.3% in treatment-naive patients — a striking result for a cancer where standard chemotherapy alone typically achieves around 23–35%. Serious side effects occurred in most patients but were manageable, and no one stopped treatment or died due to drug toxicity.
Detailed Summary
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers, with five-year survival rates below 15%. Roughly 40% of PDAC cases harbor the KRAS-G12D mutation, making it the most common oncogenic driver in this disease and a high-priority therapeutic target. Until recently, KRAS was considered 'undruggable,' but a new generation of inhibitors has changed that calculus — most are oral drugs limited by gut toxicity and insufficient tumor penetration.
HRS-4642 takes a different approach. It is a high-affinity, noncovalent KRAS-G12D inhibitor formulated as a liposomal nanoparticle for intravenous delivery. This design is engineered to improve drug accumulation within tumors and extend target inhibition, potentially overcoming the limitations of oral KRAS inhibitors.
This phase 1b/2 trial enrolled 31 patients with advanced KRAS-G12D-mutant PDAC across multiple Chinese cancer centers. In phase 1b, no dose-limiting toxicities were identified, and a dosing schedule of 500 mg on day 1 followed by 1,200 mg on day 8 every three weeks was selected as the recommended phase 2 dose. HRS-4642 was combined with nab-paclitaxel and gemcitabine, a standard chemotherapy regimen.
With a median follow-up of 12.3 months, the confirmed objective response rate among 30 treatment-naive patients reached 63.3% — well above what chemotherapy alone typically achieves and meeting the trial's primary endpoint. Grade 3 or higher treatment-related adverse events occurred in 90.3% of patients, predominantly blood-count toxicities consistent with the chemotherapy backbone. Critically, no patient discontinued treatment or died due to drug-related toxicity.
These results are clinically significant. A 63% response rate in PDAC, one of oncology's hardest challenges, would represent a meaningful advance if confirmed in larger studies. The intravenous nanoparticle formulation strategy may offer a blueprint for improving drug delivery in solid tumors more broadly. Larger, randomized trials are now warranted.
Key Findings
- 63.3% confirmed objective response rate in treatment-naive advanced KRAS-G12D pancreatic cancer patients.
- No dose-limiting toxicities identified; a clear recommended phase 2 dose was established.
- 90.3% of patients experienced grade ≥3 adverse events, but none led to treatment discontinuation or death.
- Liposomal nanoparticle formulation designed to overcome poor tumor penetration seen with oral KRAS inhibitors.
- Primary endpoint was met at median 12.3 months follow-up in this phase 1b/2 trial.
Methodology
This was an open-label, multicenter phase 1b/2 trial (NCT06520488) conducted across multiple Chinese oncology centers. Phase 1b identified the recommended dose; phase 2 evaluated efficacy with confirmed objective response rate as the primary endpoint in 30 treatment-naive patients. Sixty-eight patients were screened and 31 enrolled and treated as of the data cutoff of December 5, 2025.
Study Limitations
The trial enrolled only 31 patients, limiting statistical power and generalizability. The study was conducted exclusively in Chinese centers, and results may not generalize to other populations. Summary is based on the abstract only, as the full text was not available; detailed pharmacokinetic, biomarker, and longer-term survival data could not be assessed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: